NewLink Genetics (NASDAQ:NLNK) has been assigned a $26.00 price objective by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 205.88% from the stock’s current price.

A number of other research analysts have also issued reports on the stock. Stifel Nicolaus increased their target price on shares of NewLink Genetics from $14.00 to $29.00 and gave the stock a “buy” rating in a research report on Monday, September 11th. ValuEngine lowered shares of NewLink Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday, September 13th. Bank of America started coverage on shares of NewLink Genetics in a research report on Friday, October 13th. They set a “buy” rating and a $22.00 target price on the stock. Jefferies Group decreased their target price on shares of NewLink Genetics from $26.00 to $25.00 and set a “buy” rating on the stock in a research report on Friday, November 3rd. Finally, Zacks Investment Research lowered shares of NewLink Genetics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $23.29.

Shares of NewLink Genetics (NASDAQ NLNK) traded up $0.05 during trading hours on Monday, hitting $8.50. 606,600 shares of the company’s stock were exchanged, compared to its average volume of 1,324,283. NewLink Genetics has a 1 year low of $5.90 and a 1 year high of $25.17. The firm has a market cap of $302.63, a price-to-earnings ratio of -3.48 and a beta of 1.10.

Several hedge funds and other institutional investors have recently bought and sold shares of NLNK. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of NewLink Genetics by 1,823.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,269 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 9,735 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new stake in shares of NewLink Genetics during the 3rd quarter worth approximately $114,000. State of Wisconsin Investment Board acquired a new stake in shares of NewLink Genetics during the 2nd quarter worth approximately $125,000. Advisor Group Inc. boosted its position in shares of NewLink Genetics by 3.4% during the 2nd quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock worth $133,000 after acquiring an additional 600 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in shares of NewLink Genetics by 3.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after acquiring an additional 556 shares in the last quarter. Institutional investors and hedge funds own 52.63% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2018/01/10/cantor-fitzgerald-analysts-give-newlink-genetics-nlnk-a-26-00-price-target.html.

About NewLink Genetics

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.